Redmile Group, LLC Genmab A/S Transaction History

Redmile Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $20.5 Million - $26.3 Million	-661,621 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $16.5 Million - $21.6 Million	-458,767 Reduced 40.95%	661,621 $26.2 Million
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $4.45 Million - $5.22 Million	-107,200 Reduced 8.73%	1,120,388 $49 Million
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $3.44 Million - $4.66 Million	-104,624 Reduced 7.85%	1,227,588 $50.1 Million
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $41.2 Million - $59.2 Million	1,332,212 New	1,332,212 $43.7 Million
Q3 2020 Nov 16, 2020	SELL	$33.07 - $38.68 $35 Million - $40.9 Million	-1,057,393 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$20.05 - $33.89 $9.86 Million - $16.7 Million	-491,607 Reduced 31.74%	1,057,393 $35.8 Million
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $10.5 Million - $15.4 Million	612,300 Added 65.37%	1,549,000 $32.8 Million
Q4 2019 Feb 14, 2020	SELL	$18.88 - $24.14 $5.89 Million - $7.53 Million	-311,900 Reduced 24.98%	936,700 $20.9 Million
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $22.5 Million - $26.7 Million	1,248,600 New	1,248,600 $25.3 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.